These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 16457266)

  • 1. [Adoptive immunotherapy using MUC1--specific CTLs for unresectable pancreatic cancer].
    Kawaoka T; Takashima M; Yamamoto K; Ueno T; Oka M
    Nihon Rinsho; 2006 Jan; 64 Suppl 1():279-82. PubMed ID: 16457266
    [No Abstract]   [Full Text] [Related]  

  • 2. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1.
    Kawaoka T; Oka M; Takashima M; Ueno T; Yamamoto K; Yahara N; Yoshino S; Hazama S
    Oncol Rep; 2008 Jul; 20(1):155-63. PubMed ID: 18575732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes.
    Kondo H; Hazama S; Kawaoka T; Yoshino S; Yoshida S; Tokuno K; Takashima M; Ueno T; Hinoda Y; Oka M
    Anticancer Res; 2008; 28(1B):379-87. PubMed ID: 18383873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Adoptive immunotherapy for pancreatic cancer, using MUC1 specific CTL].
    Masaki Y; Oka M
    Gan To Kagaku Ryoho; 1996 Oct; 23(12):1679-80. PubMed ID: 8886044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunotherapy for unresectable pancreatic cancer].
    Yahara N; Oka M
    Gan To Kagaku Ryoho; 2002 Mar; 29(3):390-7. PubMed ID: 11915728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer.
    Shindo Y; Hazama S; Maeda Y; Matsui H; Iida M; Suzuki N; Yoshimura K; Ueno T; Yoshino S; Sakai K; Suehiro Y; Yamasaki T; Hinoda Y; Oka M
    J Transl Med; 2014 Jun; 12():175. PubMed ID: 24947606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes.
    Kontani K; Taguchi O; Narita T; Izawa M; Hiraiwa N; Zenita K; Takeuchi T; Murai H; Miura S; Kannagi R
    Br J Cancer; 2001 May; 84(9):1258-64. PubMed ID: 11336479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide mimics of a tumor antigen induce functional cytotoxic T cells.
    Apostolopoulos V; Lofthouse SA; Popovski V; Chelvanayagam G; Sandrin MS; McKenzie IF
    Nat Biotechnol; 1998 Mar; 16(3):276-80. PubMed ID: 9528009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
    Imai K; Hirata S; Irie A; Senju S; Ikuta Y; Yokomine K; Harao M; Inoue M; Tsunoda T; Nakatsuru S; Nakagawa H; Nakamura Y; Baba H; Nishimura Y
    Clin Cancer Res; 2008 Oct; 14(20):6487-95. PubMed ID: 18927288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Strategy of treatment for pancreatic and biliary cancer with special reference to immunotherapy].
    Oka M; Suzuki T
    Gan To Kagaku Ryoho; 1994 Aug; 21(10):1571-6. PubMed ID: 8060130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells.
    Schnurr M; Scholz C; Rothenfusser S; Galambos P; Dauer M; Röbe J; Endres S; Eigler A
    Cancer Res; 2002 Apr; 62(8):2347-52. PubMed ID: 11956095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients.
    Schmitz-Winnenthal FH; Volk C; Z'graggen K; Galindo L; Nummer D; Ziouta Y; Bucur M; Weitz J; Schirrmacher V; Büchler MW; Beckhove P
    Cancer Res; 2005 Nov; 65(21):10079-87. PubMed ID: 16267034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and localization of MUC1, MUC2, MUC5AC and small intestinal mucin antigen in pancreatic tumors.
    Yamasaki H; Ikeda S; Okajima M; Miura Y; Asahara T; Kohno N; Shimamoto F
    Int J Oncol; 2004 Jan; 24(1):107-13. PubMed ID: 14654947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Murine immune response to cells transfected with human MUC1: immunization with cellular and synthetic antigens.
    Apostolopoulos V; Xing PX; McKenzie IF
    Cancer Res; 1994 Oct; 54(19):5186-93. PubMed ID: 7923138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells.
    Jerome KR; Barnd DL; Bendt KM; Boyer CM; Taylor-Papadimitriou J; McKenzie IF; Bast RC; Finn OJ
    Cancer Res; 1991 Jun; 51(11):2908-16. PubMed ID: 1709586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer.
    Deguchi T; Tanemura M; Miyoshi E; Nagano H; Machida T; Ohmura Y; Kobayashi S; Marubashi S; Eguchi H; Takeda Y; Ito T; Mori M; Doki Y; Sawa Y
    Cancer Res; 2010 Jul; 70(13):5259-69. PubMed ID: 20530670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic tumor antigens: diagnostic markers and targets for immunotherapy.
    Finn OJ
    Important Adv Oncol; 1992; ():61-77. PubMed ID: 1374733
    [No Abstract]   [Full Text] [Related]  

  • 18. Mimic 1 of MUC1.
    Finn OJ; Gendler SJ
    Nat Biotechnol; 1998 Mar; 16(3):236-7. PubMed ID: 9527999
    [No Abstract]   [Full Text] [Related]  

  • 19. Cystic fibrosis and pancreatic cancer cells synthesize and secrete MUC1 type mucin gene product.
    Dahiya R; Kwak KS; Ho SB; Yoon WH; Kim YS
    Biochem Mol Biol Int; 1995 Feb; 35(2):351-62. PubMed ID: 7545050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intramuscular immunization with plasmid coexpressing tumour antigen and Flt-3L results in potent tumour regression.
    Fong CL; Mok CL; Hui KM
    Gene Ther; 2006 Feb; 13(3):245-56. PubMed ID: 16163376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.